22,507 research outputs found
Multimodal Machine Learning for Automated ICD Coding
This study presents a multimodal machine learning model to predict ICD-10
diagnostic codes. We developed separate machine learning models that can handle
data from different modalities, including unstructured text, semi-structured
text and structured tabular data. We further employed an ensemble method to
integrate all modality-specific models to generate ICD-10 codes. Key evidence
was also extracted to make our prediction more convincing and explainable. We
used the Medical Information Mart for Intensive Care III (MIMIC -III) dataset
to validate our approach. For ICD code prediction, our best-performing model
(micro-F1 = 0.7633, micro-AUC = 0.9541) significantly outperforms other
baseline models including TF-IDF (micro-F1 = 0.6721, micro-AUC = 0.7879) and
Text-CNN model (micro-F1 = 0.6569, micro-AUC = 0.9235). For interpretability,
our approach achieves a Jaccard Similarity Coefficient (JSC) of 0.1806 on text
data and 0.3105 on tabular data, where well-trained physicians achieve 0.2780
and 0.5002 respectively.Comment: Machine Learning for Healthcare 201
Multi-branch Convolutional Neural Network for Multiple Sclerosis Lesion Segmentation
In this paper, we present an automated approach for segmenting multiple
sclerosis (MS) lesions from multi-modal brain magnetic resonance images. Our
method is based on a deep end-to-end 2D convolutional neural network (CNN) for
slice-based segmentation of 3D volumetric data. The proposed CNN includes a
multi-branch downsampling path, which enables the network to encode information
from multiple modalities separately. Multi-scale feature fusion blocks are
proposed to combine feature maps from different modalities at different stages
of the network. Then, multi-scale feature upsampling blocks are introduced to
upsize combined feature maps to leverage information from lesion shape and
location. We trained and tested the proposed model using orthogonal plane
orientations of each 3D modality to exploit the contextual information in all
directions. The proposed pipeline is evaluated on two different datasets: a
private dataset including 37 MS patients and a publicly available dataset known
as the ISBI 2015 longitudinal MS lesion segmentation challenge dataset,
consisting of 14 MS patients. Considering the ISBI challenge, at the time of
submission, our method was amongst the top performing solutions. On the private
dataset, using the same array of performance metrics as in the ISBI challenge,
the proposed approach shows high improvements in MS lesion segmentation
compared with other publicly available tools.Comment: This paper has been accepted for publication in NeuroImag
Orally active antischistosomal early leads identified from the open access malaria box.
BACKGROUND: Worldwide hundreds of millions of schistosomiasis patients rely on treatment with a single drug, praziquantel. Therapeutic limitations and the threat of praziquantel resistance underline the need to discover and develop next generation drugs. METHODOLOGY: We studied the antischistosomal properties of the Medicines for Malaria Venture (MMV) malaria box containing 200 diverse drug-like and 200 probe-like compounds with confirmed in vitro activity against Plasmodium falciparum. Compounds were tested against schistosomula and adult Schistosoma mansoni in vitro. Based on in vitro performance, available pharmacokinetic profiles and toxicity data, selected compounds were investigated in vivo. PRINCIPAL FINDINGS: Promising antischistosomal activity (IC50: 1.4-9.5 µM) was observed for 34 compounds against schistosomula. Three compounds presented IC50 values between 0.8 and 1.3 µM against adult S. mansoni. Two promising early leads were identified, namely a N,N'-diarylurea and a 2,3-dianilinoquinoxaline. Treatment of S. mansoni infected mice with a single oral 400 mg/kg dose of these drugs resulted in significant worm burden reductions of 52.5% and 40.8%, respectively. CONCLUSIONS/SIGNIFICANCE: The two candidates identified by investigating the MMV malaria box are characterized by good pharmacokinetic profiles, low cytotoxic potential and easy chemistry and therefore offer an excellent starting point for antischistosomal drug discovery and development
Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling
Objectives: Our objective was to test the performance of CA125 in classifying serum samples from a cohort of malignant and benign ovarian cancers and age-matched healthy controls and to assess whether combining information from matrix-assisted laser desorption/ionization (MALDI) time-of-flight profiling could improve diagnostic performance.
Materials and Methods: Serum samples from women with ovarian neoplasms and healthy volunteers were subjected to CA125 assay and MALDI time-of-flight mass spectrometry (MS) profiling. Models were built from training data sets using discriminatory MALDI MS peaks in combination with CA125 values and tested their ability to classify blinded test samples. These were compared with models using CA125 threshold levels from 193 patients with ovarian cancer, 290 with benign neoplasm, and 2236 postmenopausal healthy controls.
Results: Using a CA125 cutoff of 30 U/mL, an overall sensitivity of 94.8% (96.6% specificity) was obtained when comparing malignancies versus healthy postmenopausal controls, whereas a cutoff of 65 U/mL provided a sensitivity of 83.9% (99.6% specificity). High classification accuracies were obtained for early-stage cancers (93.5% sensitivity). Reasons for high accuracies include recruitment bias, restriction to postmenopausal women, and inclusion of only primary invasive epithelial ovarian cancer cases. The combination of MS profiling information with CA125 did not significantly improve the specificity/accuracy compared with classifications on the basis of CA125 alone.
Conclusions: We report unexpectedly good performance of serum CA125 using threshold classification in discriminating healthy controls and women with benign masses from those with invasive ovarian cancer. This highlights the dependence of diagnostic tests on the characteristics of the study population and the crucial need for authors to provide sufficient relevant details to allow comparison. Our study also shows that MS profiling information adds little to diagnostic accuracy. This finding is in contrast with other reports and shows the limitations of serum MS profiling for biomarker discovery and as a diagnostic too
- …